Koers Genmab Nasdaq Copenhagen
Aandelen
DK0010272202
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 19,66 mld. 2,82 mld. 2,63 mld. | Omzet 2025 * | 23,51 mld. 3,37 mld. 3,15 mld. | Marktkapitalisatie | 127 mld. 18,18 mld. 16,98 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 5,11 mld. 732 mln. 684 mln. | Nettowinst (verlies) 2025 * | 6,76 mld. 969 mln. 905 mln. | EV/omzet 2024 * | 5,1 x |
Nettoliquiditeiten 2024 * | 26,57 mld. 3,81 mld. 3,56 mld. | Nettoliquiditeiten 2025 * | 33,5 mld. 4,8 mld. 4,49 mld. | EV/omzet 2025 * | 3,97 x |
K/w-verhouding 2024 * |
25
x | K/w-verhouding 2025 * |
19,2
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,87% |
Recentste transcriptie over Genmab
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 63 | 01-01-99 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 01-01-07 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 23-03-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 01-01-17 |
Director/Board Member | 73 | 01-11-03 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 63 | 01-01-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. | |
-24,71% | 8,24 mld. |